Accessibility Menu
Addex Therapeutics logo

Addex Therapeutics(NASDAQ) ADXN

Market Cap$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-98%
5 Year-98%
1 Year-43%
1 Month-16%
$4.95
+8.32%
+0.38Today
After hours$4.70-$0.25 (-5.05%)
Addex Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.942026-08-21
Addex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.97%USD 5.952026-08-14
1 month-16.06%USD 5.892026-07-22
3 month-27.67%USD 6.832026-05-22
Year to date-36.01%USD 7.722025-12-31
1 year-43.41%USD 8.732025-08-21
3 year-48.87%USD 9.662023-08-22
5 year-97.5%USD 197.802021-08-20
Since inception-98.3%USD 290.002020-01-29

Addex Therapeutics Financials at a Glance

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 74.04K

Net Income (TTM)

-CHF 6.97M

EPS (TTM)

-$9.31

P/E Ratio

-0.53

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$4.95

Volume

7,270,693.532

Open

$5.87

Previous Close

$4.94

Daily Range

$4.60 - $6.05

52-Week Range

$3.78 - $12.05

Estimated Earnings Date

Aug 24, 2026

ADXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Addex Therapeutics

Addex Therapeutics Ltd is a biopharmaceutical company based in Switzerland, focused on developing small-molecule drugs for central nervous system (CNS) disorders. The company specializes in discovering and advancing allosteric modulators for G-protein coupled receptors, with key programs targeting conditions such as Parkinson's disease and epilepsy.

Products and Services
  • Dipraglurant: Investigational treatment for Parkinson's disease levodopa-induced dyskinesia
  • ADX71149: Developed for epilepsy and other CNS conditions
  • GABAB PAM: A compound aimed at treating addiction
Growth Outlook
  • Strong pipeline with multiple investigational drugs in development
  • Collaborations with major partners like Janssen Pharmaceuticals and Indivior PLC
  • Focus on CNS disorders presents significant market opportunities
Financial Highlights
  • Recent quarterly revenue of 7,691 CHF, indicating ongoing development costs
  • Trailing twelve months (TTM) revenue of 36,375 CHF, reflecting early-stage commercialization
  • Cash and short-term investments totaled 937,500 CHF as of March 31, 2026
Addex Therapeutics Ltd operates in a highly specialized sector, focusing on innovative treatments for CNS disorders. The company's strategic partnerships and robust pipeline position it well for future growth. Despite current financial challenges, including negative net income and high operating expenses, the potential for breakthrough therapies in a growing market remains significant. Investors may find interest in the company's unique approach to drug development and its commitment to addressing unmet medical needs.
AI Generated • Aug 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3

CEO

Tim Dyer

Website

www.addextherapeutics.com

Headquarters

Geneva, GE 1202, CH

ADXN Financials

Key Financial Metrics (TTM)

Gross Margin

84.32%

Operating Margin

-2999.71%

Net Income Margin

-7775.20%

Return on Equity

-131.35%

Return on Capital

-58.62%

Return on Assets

-146.41%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

994.30K

Volume

7.27M

Avg. Volume

121.87K

Financials (TTM)

Gross Profit

-CHF 196.55K

Operating Income

-CHF 2.69M

EBITDA

-CHF 7.06M

Operating Cash Flow

-CHF 2.33M

Capital Expenditure

CHF 0.00

Free Cash Flow

-CHF 2.33M

Cash & ST Invst.

CHF 937.50K

Total Debt

CHF 102.27K

Addex Therapeutics Performance Analysis

Addex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 1,512,943-52.9%
20232023-12-31CHF 1,799,57118.9%
20242024-12-31CHF 465,604-74.1%
20252025-12-31CHF 208,143-55.3%
Addex Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-18.3%
Q42025-12-31-99.2%
Q12026-03-313001.2%
Addex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -57.85-2.0%
20232023-12-31CHF -18.97-67.2%
20242024-12-31CHF 5.73N/A
20252025-12-31CHF -9.05N/A
Addex Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-33.3%
Q32025-09-3030.5%
Q42025-12-317.9%
Q12026-03-3121.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CHF 7.69K

N/A

Gross Profit

-CHF 28.44K

N/A

Gross Margin

-3.70%

N/A

Market Cap

$4.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.64M

N/A

Employees

3

N/A

Net Income

-CHF 1.71M

-16.2%

EBITDA

-CHF 1.70M

-15.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CHF 937.50K

-66.9%

Total Debt

CHF 102.27K

+154.4%

Accounts Receivable

CHF 31.99K

-9.5%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 25.03K

-23.7%

Short Term Debt

CHF 77.24K

+944.1%

Return on Assets

-1.46%

N/A

Return on Invested Capital

-76.01%

N/A

Free Cash Flow

-CHF 765.84K

-27.9%

Operating Cash Flow

-CHF 765.84K

-27.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCRTAlaunos Therapeutics, Inc.
$1.76-2.22%
ADILAdial Pharmaceuticals, Inc.
$6.22+5.34%
CDIOCardio Diagnostics Holdings, Inc.
$2.03-8.14%
RADXRadiopharm Theranostics Limited
$2.44+6.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About ADXN

What is the current price of Addex Therapeutics?

Addex Therapeutics is trading at $4.94 per share.

What is the 52-week range for Addex Therapeutics?

Over the past 52 weeks, Addex Therapeutics has traded between $3.78 and $12.05.

How much debt does Addex Therapeutics have?

As of the most recent reporting period, Addex Therapeutics reported total debt of CHF 127.27K.

How much cash does Addex Therapeutics have on hand?

Addex Therapeutics reported CHF 1.16M in cash and cash equivalents in its most recent financial results.

What is Addex Therapeutics’s dividend yield?

Addex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services